Metabolic markers for liver and gall disease diagnosis

Abstract

The invention discloses metabolic markers for liver and gall disease diagnosis and a screening method thereof. The metabolic markers comprise a serum metabolic marker and a urine metabolic marker; theserum metabolic marker comprises one or any combination of EPA, AA, DHA, TCDA, DCA, GCA, TCA, GCDA, GCDCA, GDCA, CDCA, LPC16-0, LPC18-0, LPC18-1, LPC20-0. According to the screening method, a pre-established LC-MS / MS method is utilized to quantitatively detect the content of target metabolites in a clinical large sample (serum and urine), and a diagnostic marker is screened. The metabolic markerprovided by the invention can effectively diagnose liver and gall diseases, reduce the omission ratio of liver cancer and bile duct cancer, is very beneficial to early diagnosis and early treatment ofliver cancer and bile duct cancer, is greatly helpful for improving prognosis of liver cancer and bile duct cancer and reducing the mortality of liver cancer and bile duct cancer, and has good clinical application and popularization values. In practical application, more samples and more metabolite combinations can be selected for modeling according to the modeling method disclosed by the invention, so that the accuracy of the model is improved.

Description

technical field [0001] The invention belongs to the field of medical diagnosis and relates to a metabolic marker used for the diagnosis of hepatobiliary diseases. Background technique [0002] The liver is the most important metabolic organ of the human body. It is not only the most important metabolic site for endogenous metabolites (amino acids, sugars, lipids, etc.) The main detoxification organ of poison. Many factors (such as: high fat, high sugar, alcohol, chemical poisons, hepatitis virus, etc.) can cause damage to a healthy liver, and then develop into hepatitis, cirrhosis and liver cancer. With the progress of liver disease, the liver will have different metabolic phenotypes. According to the different metabolic phenotypes, the health status of the liver is divided into four levels, Phase 0 (Phase 0): healthy liver (healthy liver); Phase 1 (Phase 0). 1): Non-alcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) / alcoholic liver disease (ALD) / vir...

AI Technical Summary

Problems solved by technology

Liver function indicators (ALT, AST) reflect the functional status of the liver as the main metabolic detoxification organ, but not the level of liver lesions; while the liver cancer marker AFP is mainly used for the diagnosis and curative effect evaluation of liver cancer. There are many defects, such as: (1) poor sensitivity for the diagnosis of early liver cancer, many early liver cancer patients have very low serum AFP content (<20μg / L), and the false negative rate is about 30%; (2) the specificity is not enough, pregnancy Embryonic cancer such as testicular cancer, ovarian cancer, and very few cancers of the stomach, pancreas, bile duct, and colorectum can also increase. In addition, other liver diseases such as hepatitis and cirrhosis can also cause AFP to increase. Therefore; serum AFP is used as a marker for hepatocellular carcinoma Diagnostic markers, which are 60-70% accurate

Images